Use of Eculizumab in Patients with Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study from the SFGM-TC

Transplantation

Volumn 99, Issue 9, 2015, Pages 1953-1959

  De Fontbrune, Flore Sicre ^a   Galambrun, Claire ^b   Sirvent, Anne ^c   Huynh, Anne ^d   Faguer, Stanislas ^e   Nguyen, Stephanie ^f   Bay, Jacques Olivier ^g   Neven, Benedicte ^h   Moussi, Julie ⁱ   Simon, Laurence ^j   Xhaard, Alienor ^a   Resche Riggon, Matthieu ^a   O'Meara, Alix ^a   Fremeaux Bacchi, Veronique ^k   Veyradier, Agnes ^l   Socie, Gerard ^a   Coppo, Paul ^m   De Latour, Regis Peffaut ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b TIMONE HOSPITAL   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d CHU PURPAN   (France)

^e CHU RANGUEIL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j HÔPITAL DE HAUTEPIERRE   (France)

^k Section of Radiology   (France)

^l HÔPITAL ANTOINE BÉCLÈRE   (France)

^m SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; HAPTOGLOBIN; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; FRANCE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADVERSE EFFECTS; ALLOTRANSPLANTATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SURVIVAL; THROMBOTIC MICROANGIOPATHIES; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOTIC MICROANGIOPATHIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946895923     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000601     Document Type: Article

References (20)

1. George JN. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder. Bone Marrow Transplant 2008; 41:917.
2. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011;118:1452.
3. Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant 2010;45:689.
4. Carella AM, D'Arena G, Greco MM, Nobile M, Cascavilla N. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 2008;41:1063.
5. Cho B-S, Yahng S-A, Lee S-E, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010;90: 918.
6. Daly AS, Xenocostas A, Lipton JH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 2002; 30:709.
7. Kennedy GA, Kearey N, Bleakley S, Butler J, Mudie K, Durrant S. Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant 2010;45:699.
8. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001;27:641.
9. Sarode R, McFarland JG, Flomenberg N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995; 16:271.
10. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 2013;368:2169.
11. Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl JMed 2011;364:2561.
12. Chapin J, Weksler B, Magro C, et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012;157:772.
13. Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 2013;161:279.
14. Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014;20:518.
15. Jodele S, Davies SM, Lane A, et al. Refined diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a prospective study in children and young adults. Blood 2014;124:645.
16. Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplantassociated thrombotic microangiopathy. Blood 2013;122:2003.
17. Ricklin D, Cines DB. TMA: beware of complements. Blood 2013; 122:1997.
18. Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J 2001;2:292.
19. Van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999;93:3798.
20. Hillmen P, Muus P, Röth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013;162:62.